0000000001139262

AUTHOR

J. Malte Bumb

showing 2 related works from this author

Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study

2018

<b><i>Background:</i></b> No candidate biomarkers based on cerebrospinal fluid (CSF) have been identified as prognostic factors in patients with major depression treated with electroconvulsive therapy (ECT), yet. <b><i>Method:</i></b> Following different underlying hypotheses, we analysed baseline CSF levels of markers of neurodegeneration (tau proteins, β-amyloids and neurogranin), elements of the innate immune system (interleukin [IL]-6, neopterin, soluble CD14, soluble CD163, migration inhibitory factor and monocyte chemotactic protein 1), endocannabinoids, sphingolipids and Klotho before ECT in patients with depression (<i>n</i&gt…

MaleOncologymedicine.medical_treatmentchemistry.chemical_compound0302 clinical medicineCerebrospinal fluidElectroconvulsive therapyNeurogranincerebrospinal fluid [Sphingolipids]Electroconvulsive TherapyKlothoGlucuronidaseAged 80 and overtherapy [Depressive Disorder Major]NeopterinInterleukinMiddle AgedPsychiatry and Mental healthTreatment OutcomeNeuropsychology and Physiological Psychologycerebrospinal fluid [Biomarkers]cerebrospinal fluid [Glucuronidase]Biomarker (medicine)AntidepressantFemaleAdultmedicine.medical_specialtyklotho proteinYoung Adult03 medical and health sciencesInternal medicinemental disordersmedicineHumansddc:610Klotho ProteinsBiological Psychiatrycerebrospinal fluid [Nerve Degeneration]AgedDepressive Disorder MajorSphingolipidsbusiness.industrycerebrospinal fluid [Depressive Disorder Major]Immunity Innate030227 psychiatrychemistryNerve Degenerationcerebrospinal fluid [Endocannabinoids]businessBiomarkers030217 neurology & neurosurgeryEndocannabinoidsNeuropsychobiology
researchProduct

Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations

2014

European Community Recent years have seen considerable progress in epidemiological and molecular genetic research into environmental and genetic factors in schizophrenia, but methodological uncertainties remain with regard to validating environmental exposures, and the population risk conferred by individual molecular genetic variants is small. There are now also a limited number of studies that have investigated molecular genetic candidate gene-environment interactions (G x E), however, so far, thorough replication of findings is rare and G x E research still faces several conceptual and methodological challenges. in this article, we aim to review these recent developments and illustrate h…

URBANICITYSchizophrenia (object-oriented programming)CHILDHOODGenome-wide association studyVARIANTSSocial Environmentpsychosi03 medical and health sciences0302 clinical medicinePSYCHOSISepidemiology; gene-environment interaction; genetics; psychosis; schizophreniaSDG 3 - Good Health and Well-beingRISK-FACTORSettore M-PSI/08 - Psicologia ClinicaGenetic variationHumansGenetic Predisposition to DiseasegeneticspsychosisGENOME-WIDE ASSOCIATIONGeneSettore MED/25 - PsichiatriaMETAANALYSISScale (chemistry)schizophrenia; gene-environment interaction; Psychosis; epidemiology; geneticsGenetic variantsEnvironment and Schizophrenia InvitedCANNABIS USE3. Good health030227 psychiatrygene-environment interactionschizophreniaPsychiatry and Mental healthEvolutionary biology/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingIdentification (biology)Schizophrenic PsychologyepidemiologyPopulation RiskgeneticPsychologyFOLLOW-UP030217 neurology & neurosurgeryFUTURE-DIRECTIONSClinical psychology
researchProduct